Sep 29 2026 01:10 AM EST

Sep 29 2026 09:00 AM EST

Balance‑Sheet Wins, Trial Data and Medicare Coverage Lift Winners; Volume Weakness and Mixed Results Drag Losers

Cosan S.A. (NYSE: CSAN) rallied 8% over the past five trading days as accelerated deleveraging and a BRL 2.3 bn secondary offering improved its balance sheet, while Viking Therapeutics (NASDAQ: VKTX) jumped 36% on positive maintenance data for its VK2735 obesity candidate. CareDx (NASDAQ: CDNA) surged more than 130% in three months after an earnings beat and Medicare coverage clearance. In contrast, Beyond Meat (NASDAQ: BYND) fell more than 56% over six months amid declining U.S. demand, and Acadia Pharmaceuticals (NASDAQ: ACAD) and Celldex Therapeutics (NASDAQ: CLDX) each slipped roughly 20% after mixed trial results and cash‑burn concerns.

Balance‑Sheet Improvements Power Cosan Rally

Cosan reported a net‑debt decline to BRL 9.2 bn, a 20% reduction from the prior quarter, and gross debt fell to BRL 16.5 bn. The secondary offering of Compass Gás e Energia added BRL 2.3 bn in proceeds, while share‑buy‑backs repurchased 52.6 million shares for BRL 270.5 million. EBITDA rose ≈60% YoY to BRL 3.17 bn, offsetting a revenue shortfall. Analysts lifted 12‑month price targets to an average of $3.85, reflecting expectations that continued deleveraging and the pending Compass IPO will narrow the holding‑company discount.

VK2735 Maintenance Data Fuels Viking Surge

Viking disclosed that patients maintained up to 97% of weight loss on every‑other‑week dosing, with induction loss of 16‑22% versus 61% for placebo. The data prompted an intraday rally of roughly 36%, extending a nine‑day winning streak. The company posted a Q2 net loss of $128 million (EPS $(1.10)), beating consensus, and held $502 million in cash and short‑term investments. Analyst price targets rose to a consensus of $94‑$95, reflecting confidence that the maintenance data will support a commercial launch.

CareDx Earnings Beat and Medicare Coverage Expand Outlook

CareDx reported Q2 revenue of $132 million, up 52% YoY, and non‑GAAP EPS of $0.37, beating consensus by $0.14. Adjusted EBITDA rose to $25 million and gross margin expanded to 74%. The company raised 2026 revenue guidance to $490–$500 million, citing strong transplant‑testing growth and the finalization of a Medicare LCD for its AlloSure and AlloMap assays. The LCD removed a policy overhang, allowing analysts to lift price targets to $60‑$64 and valuing the stock at a forward P/E of 22.7x.

Volume Weakness and Margin Pressure Drag Beyond Meat

Beyond Meat posted Q2 revenue of $68.8 million, an 8.2% YoY decline driven by a 9.9% drop in U.S. retail sales and a 27.6% plunge in U.S. food‑service revenue. Gross profit fell to $5.9 million (8.5% margin) from $7.9 million a year earlier. Although operating expenses were trimmed, the company relied on a non‑recurring $57.7 million debt‑extinguishment gain to post a GAAP net income of $16.4 million. The stock has fallen more than 56% over six months, with analysts rating the stock underweight and price targets ranging from $0.50 to $10.

Mixed Trial Readouts Hit Acadia and Celldex

Acadia’s Phase 2 RADIANT trial missed its primary endpoint (12.6‑point vs 10.4‑point improvement, p = 0.0603), prompting a >20% sell‑off and analyst target cuts to an average of $33‑$35. The company nonetheless raised full‑year revenue guidance to $1.24‑$1.30 billion, driven by NUPLAZID® and DAYBUE® sales, and reported Q2 net income of $32 million.

Celldex’s Phase 3 CSU data showed a mean urticaria‑activity improvement of –20.2 points versus –10.7 for placebo and a 42.4% complete‑response rate, yet the stock fell ‑17.9% as investors focused on the absence of near‑term revenue and a cash‑burn rate that will require further financing. The company holds $717.6 million in cash, sufficient through 2028, but short interest sits at ~12% of float.

What the Five‑Day Moves Reveal

The divergent performance across the six companies underscores a split between balance‑sheet and regulatory catalysts on the upside and demand‑side weakness or mixed clinical data on the downside. Investors rewarded clear deleveraging, cash‑rich balance sheets and concrete regulatory approvals, while penalizing firms where revenue trends are deteriorating or where trial results introduce uncertainty. Continued monitoring of cash‑runway extensions, upcoming trial readouts (including Viking’s oral Phase 3 VK2735 and Celldex’s BLA filing) and macro‑economic pressures on consumer‑focused companies will determine whether the current price moves persist.